Global Blood Therapeutics is a biopharmaceutical company that focuses on developing treatments for underserved patient communities. Founded in 2011, the company's main goal is to transform the treatment and care of sickle cell disease, a lifelong inherited blood disorder. GBT has achieved this goal by introducing the first FDA-approved treatment, Oxbryta, which directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. The company is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. GBT's drug discovery teams are currently working on new targets to develop the next generation of treatments for SCD.